At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 380 enrolled
Drug / intervention
Azilsartan Medoxomildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective Study of Azilsartan Medoxomil in the Treatment of Patients With Essential Hypertension and Type 2 Diabetes in Asia
In Brief
A Phase 4 clinical trial evaluating Azilsartan Medoxomil for Essential Hypertension and Type 2 Diabetes Mellitus. Completed, enrolled 380 participants across 11 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil (AZM) in Asian adult participants with both essential hypertension and type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEssential Hypertension, Type 2 Diabetes Mellitus
CountriesChina, Taiwan, Thailand
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJul 2015
First PostedAug 2015
Primary CompletionNov 2016
Study CompletionNov 2016
TodayJul 2026
First PostedAug 7, 2015
Enrollment StartJul 13, 2015
Primary CompletionNov 15, 2016
Study CompletionNov 25, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.9 years ago
Interventions
Azilsartan Medoxomildrug
Azilsartan medoxomil tablets